ESR1 and breast cancer: Digitoxin, a cardiac glycoside, shows promise as an anticancer agent [115], while Digoxin has potential effects on BC by induceing ERα degradation, inhibits 17β-estradiol signaling, blocks the cell cycle in the G2 phase, and triggers apoptosis [116].